|
KMID : 0360319940260010082
|
|
Journal of Korean Cancer Research Association
1994 Volume.26 No. 1 p.82 ~ p.88
|
|
|
Second-line Chemotherapy with Cyclophosphamide, Adriamycin, 5-Fluorouracil, Vincristine, and Prednisolone(CAFVP) for the Advanced Breast Cancer
|
|
장홍문
김현아/김원석/허대석/방영주/김노경
|
|
|
Abstract
|
|
|
There is no effective second-line chemotherapy for the advanced breast cancer. Previously CALGB reported that CAFVP combination chemotherapy was more effective than the CMF or CMFVP combination chemotherapy for the advanced breast cancer.
So we treated 38 advanced breast cancer patients with CAFVP combination chemotherapy, who had received previous chemotherapy, between June 1979 and September 1992. Median age was 41.23 patients had prior mastectomy with adjuvant chemotherapy, 9
patients
had prior mastectomy without adjuvant chemotherapy and 6 patients had initially stage Ⅳ lesions. All had been received prior chemotherapy. The menopausal status was as follows; 29 patients were premenopausal, 9 postmenopausal. The perfomance
status was
grade 0 to 1(ECOG) in 21 patients, 2 in 17.
Treatment was cyclophosphamide 100mg/㎡ po, day 1~14, adriamycin 25mg/㎡ iv, day 1 and 8, 5-fluorouracil 400mg/㎡ iv, day 1 and 8, vincristine 1.4mg/㎡ iv, day 1 and 8, and prednisolone 60mg/day po, day 1~14. The treatment was recycled every 4
weeks
until the progression of the disease.
Among 26 patients with measurable lesions, 8(31%) achieved responses(1 CR and 7 PR). Median duration of response was 7 months. Median survival for all patients was 20 months. Toxicity was as follows: leukopenia 35%, anemia 37%, thrombocytopenia
1%,
N/V
21%. No treatment related death was observed during the treatment.
It was concluded that CAFVP combination chemotherapy is not superior to other combination chemotherapy regimens, and myelosuppression is a major dose-limiting toxicity.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|